Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Most loved Solace Food: What's Your Definitive Comfortable Dinner? - 2Figure out how to Team up with Your Auto Crash Legal advisor for Best Outcomes
- 3Midlife weight gain can start long before menopause – but you can take steps early on to help your body weather the hormonal shift
- 4The most effective method to Really Adjust Hypothesis and Practice in Your Brain science Studies
- 5December's overlooked meteor shower peaks next week — will the Ursids surprise us?
- Manual for Famous Beverages 2024
- Solar storms have influenced our history – an environmental historian explains how they could also threaten our future
- A Gustav Klimt painting is now the most expensive piece of modern art sold at auction. The fascinating history behind the $236 million 'Portrait of Elisabeth Lederer.'
- 6 Web-based Staple Help You Can Trust
- Lilly becomes first healthcare firm to join trillion-dollar club, Wall Street reacts
- 7 Heavenly Espressos, One Do You Like?
- 15 skywatching events you won't want to miss in 2026
- Consume Fat Quick: 10 Demonstrated Activities for Ideal Outcomes
- Agricultural drones are taking off globally, saving farmers time and money
